These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9776465)

  • 1. Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease.
    Müller T; Kuhn W; Büttner T; Eising E; Coenen H; Haas M; Przuntek H
    J Neurol; 1998 Oct; 245(10):659-64. PubMed ID: 9776465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients.
    Müller T; Farahati J; Kuhn W; Eising EG; Przuntek H; Reiners C; Coenen HH
    Eur Neurol; 1998; 39(1):44-8. PubMed ID: 9476723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
    Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
    Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distorted colour discrimination in Parkinson's disease is related to severity of the disease.
    Müller T; Kuhn W; Büttner T; Przuntek H
    Acta Neurol Scand; 1997 Nov; 96(5):293-6. PubMed ID: 9404998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease.
    Eising EG; Müller TT; Zander C; Kuhn W; Farahati J; Reiners C; Coenen HH
    J Investig Med; 1997 Oct; 45(8):448-52. PubMed ID: 9394097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease.
    Happe S; Baier PC; Helmschmied K; Meller J; Tatsch K; Paulus W
    J Neurol; 2007 Aug; 254(8):1037-43. PubMed ID: 17351722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.
    Asenbaum S; Brücke T; Pirker W; Podreka I; Angelberger P; Wenger S; Wöber C; Müller C; Deecke L
    J Nucl Med; 1997 Jan; 38(1):1-6. PubMed ID: 8998140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.
    Marek K; Innis R; van Dyck C; Fussell B; Early M; Eberly S; Oakes D; Seibyl J
    Neurology; 2001 Dec; 57(11):2089-94. PubMed ID: 11739831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study.
    Pirker W; Djamshidian S; Asenbaum S; Gerschlager W; Tribl G; Hoffmann M; Brücke T
    Mov Disord; 2002 Jan; 17(1):45-53. PubMed ID: 11835438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.
    Seibyl JP; Marek KL; Quinlan D; Sheff K; Zoghbi S; Zea-Ponce Y; Baldwin RM; Fussell B; Smith EO; Charney DS; van Dyck C
    Ann Neurol; 1995 Oct; 38(4):589-98. PubMed ID: 7574455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.
    Tissingh G; Bergmans P; Booij J; Winogrodzka A; van Royen EA; Stoof JC; Wolters EC
    J Neurol; 1998 Jan; 245(1):14-20. PubMed ID: 9457623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential alteration of the nigrostriatal dopaminergic system in Wilson's disease investigated with [123I]ss-CIT and high-resolution SPET.
    Barthel H; Sorger D; Kühn HJ; Wagner A; Kluge R; Hermann W
    Eur J Nucl Med; 2001 Nov; 28(11):1656-63. PubMed ID: 11702107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.